Global InformationDrotrecogin alfa information
| Clinical data | |
|---|---|
| Trade names | Xigris |
| AHFS/Drugs.com | Monograph |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 100% (i.v. application only) |
| Metabolism | endogenous plasma protease inhibitors |
| Elimination half-life | less than 2 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| IUPHAR/BPS |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| Chemical and physical data | |
| Formula | C1786H2779N509O519S29 |
| Molar mass | 40615.66 g·mol−1 |
  (what is this?) (verify) | |
Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized.[1] On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis.[2][3]
- ^ "Lilly's Shocker, or the Post-Marketing Blues". guest blog. Scientific American.
- ^ "Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy". Press release. London, UK: European Medicines Agency. 25 October 2011. Archived from the original on 28 October 2011. Retrieved 26 October 2011.
- ^ Armstrong D (October 25, 2011). "Lilly Pulls Xigris Off Markets After Sepsis Drug Fails Study". Bloomberg BusinessWeek. Archived from the original on October 29, 2011.